Pharma and Biotech Daily: GSK settles Zantac lawsuits, Bluebird Bio's gene therapy concerns, and more!
Description
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.GSK has settled Zantac lawsuits for $2.2 billion, resolving 93% of product liability cases regarding allegations that the heartburn drug could cause cancer. Analysts are now shifting focus to the company's vaccines business. In other news, pediatric patients treated with Bluebird Bio's gene therapy developed blood cancers, Pfizer's phase III prostate cancer trial re...
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Merck has committed up to $3 billion in a deal with Lanova Medicines focused on PD-1/VEGF. The deal comes as Merck faces competition from Bristol Myers Squibb in...
Published 11/15/24
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Amgen's obesity candidate, maritide, faced new safety concerns related to bone density, causing a drop in the company's stock. Biogen's shares have also plummeted due to...
Published 11/14/24